3 results
Primary objectives:* To explore the comparative bioavailability between 12.5 mg of Risperdal® Consta® prepared from a 25 mg dose strength of Risperdal® Consta® EU-sourced, and 12.5 mg of Risperdal® Consta® prepared from a 12.5 mg dose strength…
Primary objective: To compare progression-free survival (PFS) as assessed by blinded, central review between patients randomized to niraparib versus physician*s choice. Key secondary objective: To compare overall survival between patients randomized…
Primary Objective: Development of a tracer kinetic model for tracers [11C]DPA-713 and [18F]PEG-Folate.Secondary Objectives: 1. Development of a static imaging protocol and a validated simplified measure for quantification of uptake of tracers [11C]…